This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Lutetium Lu-177
DrugBank Accession Number
DB13982
Background

Not Available

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 176.9438
Monoisotopic: 176.943754987
Chemical Formula
Lu
Synonyms
  • 177Lu
  • Lu 177
  • Lu-177
  • Lutetium-177

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Lutetium chloride Lu-1771U477369SN16434-14-3AEDROEGYZIARPU-SUNKFXMWSA-K
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Endolucinbeta40 GBq/mLItm Medical Isotopes Gmb H2016-09-08Not applicableEU flag
Endolucinbeta40 GBq/mLItm Medical Isotopes Gmb H2016-09-08Not applicableEU flag
Lumark80 GBq/mLI.D.B. Radiopharmacy B.V.2020-12-22Not applicableEU flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as homogeneous lanthanide compounds. These are inorganic compounds containing only metal atoms, with the largest atom being a lanthanide atom.
Kingdom
Inorganic compounds
Super Class
Homogeneous metal compounds
Class
Homogeneous lanthanide compounds
Sub Class
Not Available
Direct Parent
Homogeneous lanthanide compounds
Alternative Parents
Not Available
Substituents
Homogeneous lanthanide
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
BRH40Y9V1Q
CAS number
14265-75-9
InChI Key
OHSVLFRHMCKCQY-NJFSPNSNSA-N
InChI
InChI=1S/Lu/i1+2
IUPAC Name
(177Lu)lutetium
SMILES
[177Lu]

References

General References
Not Available
ChemSpider
141480

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Not Yet RecruitingTreatmentNeuroendocrine Tumours (NETs)1
3RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer (CRPC)1
3RecruitingTreatmentNeuroendocrine Tumours (NETs)1
2CompletedTreatmentHepatic Metastases / Neuroendocrine Tumours (NETs)1
2CompletedTreatmentMetastatic Clear Cell Renal Cell Carcinoma1
2CompletedTreatmentProstate Cancer1
2Not Yet RecruitingTreatmentCarcinoid Tumors / Gastrinoma / Gastro Entero Pancreatic Neuroendocrine Tumors / Insulinoma / Neuroendocrine Tumours (NETs) / Pulmonary Carcinoid Tumor / Vasoactive Intestinal Peptide Tumors1
2RecruitingTreatment68Ga-PSMA PET/CT Positive / Metastatic Castration Resistant Prostate Cancer (CRPC)1
2RecruitingTreatmentCarcinoma, Adenoid Cystic / Salivary Duct Carcinoma / Salivary Gland Cancers1
2RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer (CRPC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionIntravenous40 GBq/ml
SolutionOther40 GBq/ml
SolutionOther80 GBq/ml
SolutionIntravenous
SolutionIntravenous97 GBq
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP0ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at January 20, 2018 19:24 / Updated at February 13, 2021 11:02